Disopyramide-associated liver dysfunction.
A case of disopyramide-associated cholestatic jaundice is presented, and all reported cases of disopyramide-associated liver dysfunction are reviewed. Manifestations of liver dysfunction usually appear during the first week of treatment. Discontinuing administration of the drug often results in prompt clinical resolution, although in rare instances, laboratory abnormalities persist up to 18 months. Physicians should be aware of this rare but serious complication of disopyramide therapy.
D000328:Adult; D000368:Aged; D056486:Chemical and Drug Induced Liver Injury; D002779:Cholestasis / Q000139:chemically induced* / Q000175:diagnosis; D004206:Disopyramide / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000009:adverse effects*
D011725:Pyridines; D004206:Disopyramide